文献速递肝病消化道肿瘤与早癌

恩替卡韦与替诺福韦治疗慢性乙肝患者肝细胞癌发生率无差异

No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-03-02

该回顾性研究纳入韩国9家学术医院2011至2015年收治的1560例初治慢性HBV感染患者,分别接受恩替卡韦(753例)或替诺福韦(807例)治疗,平均随访4.7±1.0年。结果显示两组HCC发生率无显著差异,倾向评分匹配后结论一致。

要点

  • 初治慢性乙肝患者接受恩替卡韦或替诺福韦治疗,HCC发生率无显著差异
  • 恩替卡韦组HCC发生率为4.5%(34例),替诺福韦组为5.6%(45例)
  • 倾向评分匹配516对后,两组HCC发生率仍无显著差异

核心结论

  • 在相同观察期内,恩替卡韦与替诺福韦治疗的初治慢性HBV感染患者HCC发生率无显著差异。

研究设计与样本

  • 回顾性研究,纳入韩国9家学术医院2011至2015年初治慢性HBV感染患者1560例,恩替卡韦组753例,替诺福韦组807例。
  • 平均随访4.7±1.0年,替诺福韦组92.4%和恩替卡韦组92.7%的患者有临床结局记录。

主要发现

  • 恩替卡韦组34例(4.5%)发生HCC,替诺福韦组45例(5.6%)发生HCC。
  • 两组HCC发生率无显著差异,在516对倾向评分匹配人群中亦无显著差异。

临床怎么用

  • 对于初治慢性乙肝患者,选择恩替卡韦或替诺福韦时,HCC风险差异不作为优先考虑因素。

局限性

  • 本研究为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Studies to evaluate risks of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection treated with the nucelos(t)ide analogues entecavir or tenofovir have produced contradictory results. These differences are likely to be the result of censored data, insufficient observation periods, and different observation periods for patients treated with different drugs. We aimed to compare the incidence of HCC development between patients treated with oral entecavir or tenofovir and followed up for the same time periods. METHODS: We performed a retrospective study, collecting data from 1560 treatment-naive patients with chronic HBV infection who were first treated with entecavir (n = 753) or tenofovir (n = 807) from 2011 through 2015 at 9 academic hospitals in Korea. Clinical outcomes were recorded over a mean time period of 4.7 ± 1.0 years, from 92.4% of patients treated with tenofovir and 92.7% of patients treated with entecavir. RESULTS: Thirty-four patients in the entecavir group (4.5%) and 45 patients in the tenofovir group (5.6%) developed HCC during the follow-up period. The incidence of HCC did not differ significantly between groups, even in a 516-pair propensity score-matched population. CONCLUSIONS: In a retrospective study of 1560 treatment-naive patients with chronic HBV infection, the incidence of HCC did not differ significantly between patients treated with entecavir vs tenofovir over the same observation period. CLINICAL TRIAL: KCT0003487.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Oh H, Yoon EL, Jun DW, et al. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir. Clin Gastroenterol Hepatol. 2020. PMID: 32135246. doi:10.1016/j.cgh.2020.02.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。